Tag: adalimumab
Sandoz and Biocon Biologics sign distribution deal for key immunology drug
Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd and a prominent player in the global biosimilars market, has entered into a pivotal Distribution Agreement ... Read More
Biocon Biologics wraps up integration of former Viatris biosimilars business
Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, has announced the successful integration of the acquired biosimilars business from Viatris in over 70 countries ... Read More
Biocon Biologics debuts biosimilar HULIO in US market
In a significant development for healthcare accessibility, Biocon Biologics Ltd (BBL), a subsidiary of Biocon, announced the availability of its biosimilar injection, HULIO (adalimumab-fkjp), in ... Read More
Pfizer, AbbVie resolve IP matters for adalimumab biosimilar
Pfizer adalimumab biosimilar update : Pfizer and AbbVie have signed licensing agreements to resolve all global intellectual property (IP) matters pertaining to the former’s proposed ... Read More
Mylan launches Humira biosimilar Hulio across Europe
Mylan has launched Hulio, a biosimilar to AbbVie's Humira (adalimumab), in major markets in Europe, a month after its approval from the European Commission for ... Read More
Humira biosimilar Cyltezo meets objective in phase 3 plaque psoriasis trial
German pharma company Boehringer Ingelheim said that Cyltezo, a biosimilar to AbbVie psoriasis drug Humira, achieved clinical equivalence to the reference product in a phase ... Read More
Hyrimoz EC approval : Novartis biosimilar of AbbVie Humira approved in EU
Hyrimoz EC approval : Novartis’ Sandoz has bagged approval for Hyrimoz (adalimumab), a biosimilar of AbbVie’s Humira (adalimumab), in Europe for all indications of the ... Read More